Engineered Ionizable Lipid Nanoparticles for Targeted Delivery of RNA Therapeutics into Different Types of Cells in the Liver

Overview

Journal Sci Adv

Specialties Biology
Science

Date 2021 Feb 27

PMID 33637537

Citations 108

Authors

M Kim

M Jeong

S Hur

Y Cho

J Park

H Jung

Y Seo

H A Woo

K T Nam

K Lee

H Lee

Affiliations

Soon will be listed here.

Abstract

Ionizable lipid nanoparticles (LNPs) have been widely used for in vivo delivery of RNA therapeutics into the liver. However, a main challenge remains to develop LNP formulations for selective delivery of RNA into certain types of liver cells, such as hepatocytes and liver sinusoidal endothelial cells (LSECs). Here, we report the engineered LNPs for the targeted delivery of RNA into hepatocytes and LSECs. The effects of particle size and polyethylene glycol-lipid content in the LNPs were evaluated for the hepatocyte-specific delivery of mRNA by ApoE-mediated cellular uptake through low-density lipoprotein receptors. Targeted delivery of RNA to LSECs was further investigated using active ligands. Incorporation of mannose allowed the selective delivery of RNA to LSECs, while minimizing the unwanted cellular uptake by hepatocytes. These results demonstrate that engineered LNPs have great potential for the cell type-specific delivery of RNA into the liver and other tissues.

Citing Articles

Berberine-inspired ionizable lipid for self-structure stabilization and brain targeting delivery of nucleic acid therapeutics.

Bian X, Guo Q, Yau L, Yang L, Wang X, Zhao S Nat Commun. 2025; 16(1):2368.

PMID: 40064874 PMC: 11893799. DOI: 10.1038/s41467-025-57488-0.

Developing mRNA Nanomedicines with Advanced Targeting Functions.

Wang J, Cai L, Li N, Luo Z, Ren H, Zhang B Nanomicro Lett. 2025; 17(1):155.

PMID: 39979495 PMC: 11842722. DOI: 10.1007/s40820-025-01665-9.

CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations.

Lee H, Rho W, Kim Y, Chang H, Jun B Molecules. 2025; 30(3).

PMID: 39942646 PMC: 11820414. DOI: 10.3390/molecules30030542.

LBP-CD155 Liposome Nanovaccine Efficiently Resist Colorectal Cancer and Enhance ICB Therapy.

Yan Y, Duan T, Xue X, Yang X, Liu M, Ma B Int J Nanomedicine. 2025; 20:1047-1063.

PMID: 39877587 PMC: 11773180. DOI: 10.2147/IJN.S492734.

Branched endosomal disruptor (BEND) lipids mediate delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complex for hepatic gene editing and T cell engineering.

Padilla M, Mrksich K, Wang Y, Haley R, Li J, Han E Nat Commun. 2025; 16(1):996.

PMID: 39856035 PMC: 11759712. DOI: 10.1038/s41467-024-55137-6.

References

Li B, Luo X, Deng B, Wang J, McComb D, Shi Y . An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo. Nano Lett. 2015; 15(12):8099-107. PMC: 4869688. DOI: 10.1021/acs.nanolett.5b03528. View

Cheng Q, Wei T, Jia Y, Farbiak L, Zhou K, Zhang S . Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I. Adv Mater. 2018; 30(52):e1805308. DOI: 10.1002/adma.201805308. View

Seth P, Tanowitz M, Bennett C . Selective tissue targeting of synthetic nucleic acid drugs. J Clin Invest. 2019; 129(3):915-925. PMC: 6391085. DOI: 10.1172/JCI125228. View

Kristen A, Ajroud-Driss S, Conceicao I, Gorevic P, Kyriakides T, Obici L . Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener Dis Manag. 2018; 9(1):5-23. DOI: 10.2217/nmt-2018-0033. View

Love K, Mahon K, Levins C, Whitehead K, Querbes W, Dorkin J . Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A. 2010; 107(5):1864-9. PMC: 2804742. DOI: 10.1073/pnas.0910603106. View

Gan L, Lagerstrom-Fermer M, Carlsson L, Arfvidsson C, Egnell A, Rudvik A . Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nat Commun. 2019; 10(1):871. PMC: 6382754. DOI: 10.1038/s41467-019-08852-4. View

Yin H, Song C, Suresh S, Wu Q, Walsh S, Rhym L . Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol. 2017; 35(12):1179-1187. PMC: 5901668. DOI: 10.1038/nbt.4005. View

Ray K, Stoekenbroek R, Kallend D, Leiter L, Landmesser U, Wright R . Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. Circulation. 2018; 138(13):1304-1316. DOI: 10.1161/CIRCULATIONAHA.118.034710. View

Choi K, Correa S, Min J, Li J, Roy S, Laccetti K . Binary Targeting of siRNA to Hematologic Cancer Cells using Layer-by-Layer Nanoparticles. Adv Funct Mater. 2019; 29(20). PMC: 6910249. DOI: 10.1002/adfm.201900018. View

10.

Fernandez N, Alonso S, Valera I, Vigo A, Renedo M, Barbolla L . Mannose-containing molecular patterns are strong inducers of cyclooxygenase-2 expression and prostaglandin E2 production in human macrophages. J Immunol. 2005; 174(12):8154-62. DOI: 10.4049/jimmunol.174.12.8154. View

11.

Kauffman K, Dorkin J, Yang J, Heartlein M, DeRosa F, Mir F . Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. Nano Lett. 2015; 15(11):7300-6. DOI: 10.1021/acs.nanolett.5b02497. View

12.

Hattori Y, Suzuki S, Kawakami S, Yamashita F, Hashida M . The role of dioleoylphosphatidylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route. J Control Release. 2005; 108(2-3):484-95. DOI: 10.1016/j.jconrel.2005.08.012. View

13.

Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Narayanannair Jayaprakash K . Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010; 18(7):1357-64. PMC: 2911264. DOI: 10.1038/mt.2010.85. View

14.

Poisson J, Lemoinne S, Boulanger C, Durand F, Moreau R, Valla D . Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J Hepatol. 2016; 66(1):212-227. DOI: 10.1016/j.jhep.2016.07.009. View

15.

Ramaswamy S, Tonnu N, Tachikawa K, Limphong P, Vega J, Karmali P . Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci U S A. 2017; 114(10):E1941-E1950. PMC: 5347596. DOI: 10.1073/pnas.1619653114. View

16.

Dong Y, Love K, Dorkin J, Sirirungruang S, Zhang Y, Chen D . Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci U S A. 2014; 111(11):3955-60. PMC: 3964096. DOI: 10.1073/pnas.1322937111. View

17.

Tanoi T, Tamura T, Sano N, Nakayama K, Fukunaga K, Zheng Y . Protecting liver sinusoidal endothelial cells suppresses apoptosis in acute liver damage. Hepatol Res. 2015; 46(7):697-706. DOI: 10.1111/hepr.12607. View

18.

Jin J, Wu X, Yin J, Li M, Shen J, Li J . Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. Front Oncol. 2019; 9:263. PMC: 6477148. DOI: 10.3389/fonc.2019.00263. View

19.

Alabi C, Love K, Sahay G, Yin H, Luly K, Langer R . Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery. Proc Natl Acad Sci U S A. 2013; 110(32):12881-6. PMC: 3740846. DOI: 10.1073/pnas.1306529110. View

20.

Finn J, Rhoden Smith A, Patel M, Shaw L, Youniss M, van Heteren J . A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. Cell Rep. 2018; 22(9):2227-2235. DOI: 10.1016/j.celrep.2018.02.014. View